The Necrotizing Enterocolitis drugs in development market research report provides comprehensive information on the therapeutics under development for Necrotizing Enterocolitis, complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA), and molecule type. GlobalData’s report assesses key aspects of the companies and drugs in development for Necrotizing Enterocolitis. Buy the report here.
Smarter leaders trust GlobalData
The report also covers the descriptive pharmacological action of the therapeutics and the latest news and press releases. Additionally, the report provides an overview of the key players involved in therapeutic development for Necrotizing Enterocolitis and features dormant and discontinued products.
GlobalData tracks 14 drugs in development for Necrotizing Enterocolitis by 14 companies/universities/institutes. The top development phase for Necrotizing Enterocolitis is preclinical with ten drugs in that stage. The Necrotizing Enterocolitis pipeline has 13 drugs in development by companies and one by universities/ institutes. Some of the companies in the Necrotizing Enterocolitis pipeline products market are: Leadiant Biosciences, Liminal BioSciences and University of Pittsburgh.
The key targets in the Necrotizing Enterocolitis pipeline products market include Toll Like Receptor 4, Interleukin 22 Receptor, and Alpha 1 Antitrypsin.
The key mechanisms of action in the Necrotizing Enterocolitis pipeline product include Toll Like Receptor 4 Antagonist with one drug in Preclinical. The Necrotizing Enterocolitis pipeline products include eight routes of administration with the top ROA being Oral and five key molecule types in the Necrotizing Enterocolitis pipeline products market including Biologic, and Small Molecule.
Necrotizing Enterocolitis overview
Necrotizing Enterocolitis is the most common type of infection seen in neonates where inflammation of the intestine leads to mucosal damage causing necrosis or death of cells and tissues. Most observed in premature neonates or in infants weighing less than 1500g leading the mortality rate to greater than 50 percent. Genetic mutations also play a role in this condition. Bacterial invasion into the intestinal wall is the major cause of this condition. It could lead to sepsis and ultimately death. Signs and symptoms are variable and non-specific but most commonly fatigueness, dullness or decreased activity, vomiting, and blood in stool are the common symptoms observed. Diagnosis is an abdominal examination, CBP count, stool examination to find out the pathogens, breath hydrogen test and other radiographic findings. Initial course of management is NPO (nothing by mouth), airway, breathing and circulation support in extreme conditions, antibiotics, IV fluids. Surgical intervention in complicated cases.
For a complete picture of Necrotizing Enterocolitis’s pipeline drug market, buy the report here.
Data Insights
From
The gold standard of business intelligence.
Blending expert knowledge with cutting-edge technology, GlobalData’s unrivalled proprietary data will enable you to decode what’s happening in your market. You can make better informed decisions and gain a future-proof advantage over your competitors.
GlobalData, the leading provider of industry intelligence, provided the underlying data, research, and analysis used to produce this article.
GlobalData’s pipeline drugs offers detailed profiles of pharmaceutical drugs in all stages of pre-clinical and clinical development, from discovery through to pre-registration. Coverage is limited to novel human medicinal drugs and biosimilars seeking market approval proprietary and is one of two primary repositories of pharmaceutical drug information offered by GlobalData through its Pharmaceutical Intelligence Center.
